Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Ранг среди акций #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Цена акции
$2.65
Последняя синхронизация: 2024-04-03
Рыночная капитализация
$115.71M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Kinnate Biopharma Inc. (KNTE)

Категория

Коэффициент P/S для Kinnate Biopharma Inc. (KNTE)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Kinnate Biopharma Inc., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Kinnate Biopharma Inc. с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH